AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may underpin the company's 18% share price increase over the last quarter. The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment, RINVOQ®. Concurrently, broader market trends reflect a more modest movement, with major indices experiencing minor fluctuations as investors navigate economic data and tariff updates. While the S&P 500 and Nasdaq showed slight losses, the market's yearly upward trajectory contrasts with AbbVie's strong share performance. Additionally, the company's financial maneuvers, including major public offerings and credit expansions, underscore a bolstered financial position, possibly reinforcing investor confidence amidst these developments.

Click to explore a detailed breakdown of our findings on AbbVie.

Over the last five years, AbbVie's total shareholder return reached 192.95%, showcasing a strong performance. This achievement comes amidst varied developments that have shaped the company's trajectory. Notably, AbbVie's consistent dividend increases, including the $1.64 declared in February, reflect ongoing shareholder value enhancement strategies. Additionally, AbbVie completed significant share repurchases amounting to US$16.5 billion, further underscoring its commitment to returning capital to investors. This comprehensive approach has set AbbVie apart from industry peers, outperforming both the broader market and its sector over the past year.

Diversified product development has also played a crucial role, with key approvals like SKYRIZI® for multiple indications in Canada and the FDA approval of EMBLAVEO™ addressing critical market needs. The ongoing collaboration with REGENXBIO and other strategic partnerships have likely bolstered its R&D capabilities. Despite executive transitions and legal challenges like the Humira pricing inquiries, AbbVie's focus on research innovation and financial strategies remains a critical driver of its robust long-term returns.

• Unlock the insights behind AbbVie's valuation and discover its true investment potential
• Assess the potential risks impacting AbbVie's growth trajectory—explore our risk evaluation report.
• Have a stake in AbbVie? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:ABBV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com